


Stabilis



Flucloxacillin sodium



Noms commerciaux

| | |
|---------------------------|--|
| Astaph | Maroc |
| Betabiotic | Italie |
| DBL flucloxacillin sodium | Australie |
| Flix | Turquie |
| Floxam | Maroc |
| Floxapen | Arabie Saoudite, Autriche, Belgique, Etats Unis d'Amérique, Italie, Maroc, Pays bas, Pologne, Portugal, Suisse |
| Flucloxacillin | Allemagne, Grande Bretagne, Italie |
| Flucloxacilline | Pays bas |
| Flucloxin | Nouvelle Zélande |
| Ladropen | Etats Unis d'Amérique |
| Stafoxil | Pays bas |
| Staphylex | Allemagne |



Stabilité des solutions

| PVC | ▲ | 120 mg/ml | 2-8°C | ? | 6 | ☉ | | 3189 |
|-----|---------------|-------------------|---------|---|-----|---|--|------|
| PVC | ▲ | 20 mg/ml | -27°C | ☉ | 270 | ☉ | | 1349 |
| PVC | ▲ | 5 & 10 & 20 mg/ml | 5°C | ☉ | 21 | ☉ | | 1494 |
| PVC | ◆ | 20 mg/ml | -27°C | ☉ | 90 | ☉ | | 1349 |
| PP | ▲ | 10 mg/ml | 2-8°C | ☉ | 14 | ☉ | | 1845 |
| PP | ▲ | 10 mg/ml | 25°C | ☉ | 4 | ☉ | | 1845 |
| PP | 💧 | 140 mg/ml | 4°C-8°C | ☉ | 9 | ☉ | | 1300 |
| PI | ▲ | 50 mg/ml | 2-8°C | ? | 6 | ☉ | | 3189 |
| PI | ▲ 0.3% pH7 | 10 & 50 mg/ml | 2-8°C | ? | 13 | ☉ | | 4218 |
| PI | ▲ 0.3% pH7 | 10 & 50 mg/ml | 32°C | ? | 24 | ☑ | | 4218 |
| PI | ▲ 0.3% pH7 | 5 & 60 mg/ml | 2-8°C | ☉ | 6 | ☉ | | 4590 |
| PI | ▲ 0.3% pH7 | 5 & 60 mg/ml | 37°C | ☉ | 24 | ☑ | | 4590 |
| SI | ▲ 0.3% pH7 | 10 & 50 mg/ml | 2-8°C | ? | 13 | ☉ | | 4218 |



Facteur influençant la stabilité




| | | | | |
|--|----------|--|--|------|
| | | | | 3522 |
| | | | | 3522 |
| | 37°C | | | 3189 |
| | PH = 6,5 | | | 3189 |



Compatibilités

| | | | 3522 |
|--|--|--|------|
| | | | 1232 |
| | | | 1232 |
| | | | 1232 |
| | | | 1232 |
| | | | 1232 |
| | | | 3091 |
| | | | 1232 |
| | | | 1232 |
| | | | 1232 |
| | | | 3529 |
| | | | 1232 |
| | | | 1232 |
| | | | 3674 |
| | | | 3522 |
| | | | 1357 |
| | | | 3522 |

| | | | |
|--|--|--|------|
| | Flucloxacillin sodium : 20 mg/ml Dexamethasone sodium phosphate : 4 mg/ml | | 1232 |
| | Flucloxacillin sodium : 20 mg/ml Digoxin : 25 µg/ml | | 1232 |
| | Flucloxacillin sodium : 20 mg/ml Epinephrine hydrochloride : 8 µg/ml | | 1232 |
| | Flucloxacillin sodium : 20 mg/ml Furosemide : 1 mg/ml | | 1232 |
| | Flucloxacillin sodium : 50 mg/ml | | 939 |
| | Flucloxacillin sodium Gentamicin sulfate | | 3522 |
| | Flucloxacillin sodium Gentamicin sulfate | | 3643 |
| | Flucloxacillin sodium : 20 mg/ml Hydrocortisone sodium succinate : 50 mg/ml | | 1232 |
| | Flucloxacillin sodium Kanamycin sulfate | | 3522 |
| | Flucloxacillin sodium : 20 mg/ml Lidocaine hydrochloride : 2 mg/ml | | 1232 |
| | Flucloxacillin sodium : 50 mg/ml Lorazepam : 0.33 mg/ml | | 186 |
| | Flucloxacillin sodium : 20 mg/ml Metoclopramide hydrochloride : 1 mg/ml | | 1232 |
| | Flucloxacillin sodium : 50 mg/ml Midazolam hydrochloride : 5 mg/ml | | 186 |
| | Flucloxacillin sodium Netilmicin sulfate | | 3522 |
| | Flucloxacillin sodium : 10 mg/ml Ofloxacin : 2 mg/ml | | 889 |
| | Flucloxacillin sodium Penicillin G sodium | | 3585 |
| | Flucloxacillin sodium : 50 mg/ml Pentoxifyllin : 5 mg/ml | | 4538 |
| | Flucloxacillin sodium : 20 mg/ml Pethidine hydrochloride : 5 mg/ml | | 1232 |
| | Flucloxacillin sodium : 20 mg/ml Potassium chloride : 40 mEq/l | | 1232 |
| | Flucloxacillin sodium : 20 mg/ml Prochlorperazine edisylate : 1.25 mg/ml | | 1232 |
| | Flucloxacillin sodium : 20 mg/ml Promethazine hydrochloride : 5 mg/ml | | 1232 |
| | Flucloxacillin sodium : 20 mg/ml Ranitidine hydrochloride : 0,5 mg/ml | | 1232 |
| | Flucloxacillin sodium : 20 mg/ml Sodium bicarbonate : 84 mg/ml | | 1232 |
| | Flucloxacillin sodium : 250 mg/ml Temocilline : 83.33 mg/ml | | 2231 |
| | Flucloxacillin sodium Tobramycin sulfate | | 3522 |
| | Flucloxacillin sodium : 20 mg/ml Tobramycin sulfate : 8 mg/ml | | 1232 |

| | | | | |
|--|--|--|---|------|
|  |  | Flucloxacillin sodium : 250 mg/ml Vancomycin hydrochloride : 10 mg/ml |  | 3385 |
|--|--|--|---|------|



Voie d'administration





















































Bibliographie

| | Type | Source |
|------|-------|---|
| 186 | Revue | Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022. |
| 889 | Revue | Janknegt R, Stratermans T, Cilissen J, Lohman JJHM, Hooymans PM. Ofloxacin intravenous. Compatibility with other antibacterial agents. Pharm Weekbl [Sci] 1991 ; 13: 207-209. |
| 939 | Revue | Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170. |
| 1232 | Revue | Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236. |
| 1300 | Revue | Ahmed ST, Parkinson R. The stability of drugs in pre-filled syringes: flucloxacillin, ampicillin, cefuroxime, cefotaxime and ceftazidime. Hosp Pharm Pract 1992 ; 2: 285-289. |
| 1349 | Revue | Sanburg AL, LyndonRC, Sunderland B. Effects of freezing, long term storage and microwave thawing on the stability of three antibiotics reconstituted in minibags. Aust J Hosp Pharm 1987 ; 17: 31-34. |
| 1357 | Revue | Janknegt R, Schrouff GGM, Hooymans PM, Hermens WJHH, Lohman JJHM. Quinolones and penicillins incompatibility. Ann Pharmacotherapy 1989 ; 23: 91-92. |
| 1494 | Revue | McLaughlin JP, Simpson C. When is flucloxacillin stable ? Hosp Pharm Pract 1993 ; 3: 553-556. |
| 1845 | Revue | Müller HJ, Haker I. The stability of amoxicillin, ampicillin, benzylpenicillin, flucloxacillin, mezlocillin and piperacillin in isotonic saline solutions when stored in an innovative infusion container (Freeflex container). EJHP 2003 ; 6: 106-111. |
| 2231 | Revue | de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388. |

| | | |
|------|-------------|--|
| 3091 | Revue | Thalhammer F, Maier-Salamon A, Jäger W. Prüfung von Stabilität und Kompatibilität von Flucloxacillin (Floxapen®) und Cefprozidim (Fortum®) in zwei Infusionslösungen: Relevanz für die klinische Praxis. Wien Med Wochenschr 2005 ; 155, 13-14: 337-343. |
| 3189 | Revue | Tho T-P, Ching MS, Elis AG, Williams L, Garrett MK. Stability of intravenous flucloxacillin solutions used for hospital-in-the-home. J Pharm Pract and Res 2010 ; 40, 2: 101-105. |
| 3385 | Revue | Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182. |
| 3522 | Laboratoire | Flucloxacillin - Summary of Product Characteristics. Actavis 2013 |
| 3529 | Laboratoire | Ciprofloxacin – Summary of Product Characteristics Hospira 2013 |
| 3585 | Laboratoire | Benzylpenicillin sodium - Summary of Product Characteristics Genus Pharmaceuticals 2008 |
| 3643 | Laboratoire | Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015 |
| 3674 | Laboratoire | Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016 |
| 4218 | Revue | Allwood M.C, Stonkute D, Wallace A, Wilkinson A-S, Hills T, Jamieson C, Assessment of the stability of citrate-buffered flucloxacillin for injection when stored in two commercially available ambulatory elastomeric devices: INFUSOR LV (Baxter) and ACCUFUSER (Woo Young Medical): a study compliant with the NHS Yellow Cover Document (YCD) requirements. EJHP 2020 ; 27, 2: 90-94. |
| 4538 | Revue | Campbell A, Petrovski M, Senarathna G, Mukadam , Strunk T, Batty K. Compatibility of pentoxifylline and parenteral medications. Archives of Disease in Childhood 2020 ; 105: 395-397. |
| 4590 | Revue | Smith E.K, McWhinney MPhil B.C. Stability of buffered benzylpenicillin and flucloxacillin for a paediatric outpatient parenteral antibiotic therapy service. J Pediatr Pharmacol Ther 2021 ; 51: 231-237. |



Dictionnaire

| | |
|--|---|
|  Antibiotique |  Injectable |
|  Noms commerciaux |  Stabilité des solutions |
|  Contenant |  Molécule |
|  Concentration |  Température |
|  Conservation |  Durée de stabilité |
|  Biosimilaire |  Données conflictuelles |
|  Bibliographie |  Polyvinyl chlorure |
|  Chlorure de sodium 0,9% |  Non précisée |
|  Jour |  A l'abri de la lumière |
|  Glucose 5% |  Polypropylène |
|  Seringue polypropylène |  Eau pour préparation injectable |
|  Elastomère en polyisoprène |  NaCl 0.9% tampon citrate 0.3% pH7 |
|  Heure |  Elastomère en silicone |
|  Facteur influençant la stabilité |  Solvant |
|  Nutrition parentérale (mélange ternaire) |  Provoque |
|  Dégradation |  Nutrition parentérale (mélange binaire) |
|  Augmentation stabilité |  Compatibilités |
|  Molécule |  Précipitation immédiate |
|  Incompatible |  Compatible |
|  Incompatibilité non précisée |  Turbidité immédiate |
|  Aucun |  Turbidité en 4 heures |
|  Précipitation en 7 heures |  Voie d'administration |
|  Intraveineuse |  Perfusion intraveineuse |
|  Intramusculaire |  Intrapleurale |
|  Intraarticulaire |  Bibliographie |
|  Dictionnaire | |